サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1555474

インフルエンザ治療薬市場：薬剤タイプ別、インフルエンザタイプ別、年齢層別、投与経路別、流通チャネル別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Influenza Medications Market, By Drug Type, By Influenza Type, By Age Group, By Route of Administration, By Distribution Channel and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 399 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
インフルエンザ治療薬市場：薬剤タイプ別、インフルエンザタイプ別、年齢層別、投与経路別、流通チャネル別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年08月20日
発行: AnalystView Market Insights
ページ情報: 英文 399 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

2023年のインフルエンザ治療薬の市場規模は9億3,243万米ドルで、2024年から2032年にかけてCAGR 7.2％で拡大

インフルエンザ治療薬市場-市場力学

インフルエンザ罹患率の増加が市場成長を牽引すると予測

インフルエンザは、季節的に繰り返し発症する病気であり、世界各地のさまざまな地域で毎年流行しています。インフルエンザの季節に発生率が高まるため、医薬品による介入に対する需要が増加します。さらに、散発的なインフルエンザのパンデミックや流行は、インフルエンザの発生率を大幅に上昇させる可能性があり、その結果、抗ウイルス療法や予防戦略の必要性が急増します。米国疾病予防管理センター（CDC）は、今シーズンのインフルエンザによる患者数は少なくとも3,500万人、入院者数は40万人、死亡者数は2万5,000人と推定しています。さらに、抗ウイルス薬や総合的な治療手法の開発における進歩は、市場に大きな成長機会をもたらしています。とはいえ、新薬に伴う高コストが市場拡大の課題となる可能性もあります。

インフルエンザ治療薬市場-主な洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約7.2%のCAGRで毎年成長すると推定されます。

薬剤タイプ別では、抗ウイルス薬が2023年に最大の市場シェアを示すと予測されます。

インフルエンザのタイプ別では、2023年にはインフルエンザA型が主要なタイプとなっています。

年齢層別では、2023年には成人が主要タイプでした。

投与経路のセグメンテーションに基づくと、2023年には経口剤が主要タイプでした。

流通チャネル別では、2023年には病院薬局が主要タイプとなっています。

地域別では、北米が2023年に収益でリードしました。

インフルエンザ治療薬市場-セグメンテーション分析：

世界のインフルエンザ治療薬市場は、薬剤タイプ、インフルエンザタイプ、年齢層、投与経路、流通チャネル、地域に基づいてセグメント化されます。

市場は薬剤タイプによって3つに分類される：抗ウイルス薬、抗ヒスタミン薬、鎮痛・解熱薬です。抗ウイルス薬は市場で圧倒的な地位を占めています。これらの薬剤は、インフルエンザの症状の強さや長さを緩和するために処方され、場合によっては合併症を回避することもあります。

市場は、インフルエンザのタイプによって2つのセグメントに分類される：インフルエンザA型とインフルエンザB型です。A型インフルエンザは、毎年のインフルエンザ流行の引き金となる役割を担っており、その急速な変異能力によりパンデミックを引き起こす能力を持っていることが認識されています。

市場は年齢層によって3つのセグメントに分類される：成人、小児、老年です。成人は市場を独占しています。成人は季節性インフルエンザに頻繁に罹患し、その重症度は年齢、基礎疾患、ワクチン接種歴などの要因に影響されることから、成人に焦点を当てたインフルエンザ治療薬市場は極めて重要なセグメントです。

市場は投与経路によって3つのカテゴリーに分類される：経口、吸入、静脈内です。市場では経口剤が圧倒的な地位を占めています。経口抗ウイルス薬は、特に軽症から中等症の治療において、インフルエンザ対策の主要な選択肢となることが多いです。

市場は流通チャネルによって3つのカテゴリーに分類される：病院薬局、小売薬局、オンライン薬局です。病院薬局が市場を独占しています。病院では、高齢者、持病のある人、免疫力が低下している人など、重症化するリスクが高い患者を治療するために、効率的な抗ウイルス治療が必要とされています。

インフルエンザ治療薬市場-地理的洞察

同市場は、北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカを含む広範な地域にまたがっています。これらの地域は、事業活動に貢献している国々に基づいてさらに分類されます。北米は、先進的な薬物療法の採用とヘルスケア支出の増加により、市場をリードしています。北米、特に米国の規制枠組みは、新型インフルエンザ治療の迅速な承認と実施を促進しています。これには、他の地域ではまだ利用できない革新的な治療法へのアクセスも含まれます。2022年には、新薬と呼ばれる合計37の新薬が米国で初めて承認されました。さらに、米国国立衛生統計センターの報告によると、すでに承認された薬剤が、新たな適応症や患者層を含む新たな用途で承認されました。欧州は、認知度の向上と早期診断の増加により、市場拡大の第2位の地域となっています。

インフルエンザ治療薬市場-競合情勢：

インフルエンザ治療薬市場は、特に抗ウイルス剤分野において、より大きなシェアを確保しようとする多数の製薬企業によって特徴づけられる高いレベルの競合を示します。この競争の重要な焦点は、独自の作用メカニズムを採用した新しい抗ウイルス薬の技術革新にあります。耐性を克服し、有効性や利便性を向上させることができる高度なインフルエンザ治療薬を処方するための研究開発にリソースを割いている企業は、将来の市場機会を獲得するために戦略的なポジショニングをとっています。さらに、これらの企業は、人口が多く、インフルエンザの罹患率が上昇している新興市場において確固たるプレゼンスを確立しようと努力しています。また、特にインフルエンザの流行期には、早期抗ウイルス薬介入の利点に関する認知を促進するために、各社が協調して取り組んでいます。

目次

第1章 インフルエンザ治療薬市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 インフルエンザ治療薬の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 インフルエンザ治療薬業界の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 インフルエンザ治療薬市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 インフルエンザ治療薬市場情勢

  • インフルエンザ治療薬市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 インフルエンザ治療薬市場- 薬剤タイプ別

  • 概要
    • 医薬品タイプ別セグメントシェア分析
    • 抗ウイルス薬
      • シングル抗ウイルス薬
      • 抗ウイルス薬の併用
    • 抗ヒスタミン薬
    • 鎮痛剤
    • 解熱剤

第8章 インフルエンザ治療薬市場- インフルエンザタイプ別

  • 概要
    • インフルエンザタイプ別セグメントシェア分析
    • インフルエンザA
    • インフルエンザB

第9章 インフルエンザ治療薬市場- 年齢層別

  • 概要
    • 年齢層別セグメントシェア分析
    • 大人
    • 小児科
    • 高齢者

第10章 インフルエンザ治療薬市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 経口
    • 吸入
    • 静脈内

第11章 インフルエンザ治療薬市場- 流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第12章 インフルエンザ治療薬市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析- インフルエンザ治療薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • AstraZeneca plc
    • Teva Pharmaceutical Industries Ltd
    • BioCryst Pharmaceuticals, Inc.
    • Sanofi
    • Daiichi Sankyo Company
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • NATCO Pharma Limited
    • GlaxoSmithKline plc
    • Lupin
    • Others

第14章 アナリストの全方位展望

目次
Product Code: ANV3636

REPORT HIGHLIGHT

Influenza Medications Market size was valued at USD 932.43 million in 2023, expanding at a CAGR of 7.2% from 2024 to 2032.

Medications for influenza are utilized to either treat or prevent infections caused by the flu. Antiviral drugs that target influenza viruses serve as a crucial complement to the influenza vaccine in managing the disease. These antiviral agents function by hindering the replication of the influenza virus, which in turn alleviates the severity and shortens the duration of symptoms. Their efficacy is maximized when administered promptly, preferably within 48 hours of the onset of symptoms. Thus, influenza medications play a vital role in alleviating flu symptoms and mitigating the overall effects of the infection.

Influenza Medications Market- Market Dynamics

The increasing incidence of influenza is expected to drive the growth of the market

Influenza is a recurring illness that manifests seasonally, resulting in annual outbreaks across various regions globally. The heightened occurrence during the flu season leads to an increased demand for pharmaceutical interventions. Additionally, sporadic flu pandemics or epidemics can considerably elevate the incidence of influenza, resulting in surges in the need for antiviral therapies and preventive strategies. The Centers for Disease Control and Prevention (CDC) estimates that this season has witnessed at least 35 million cases, 400,000 hospitalizations, and 25,000 fatalities attributed to the flu. Moreover, advancements in the development of antiviral medications and integrated treatment methodologies present significant growth opportunities for the market. Nonetheless, the high costs associated with novel medications may pose challenges to market expansion.

Influenza Medications Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.2% over the forecast period (2024-2032)

Based on Drug Type segmentation, Antiviral drugs were predicted to show maximum market share in the year 2023

Based on Influenza Type segmentation, Influenza A was the leading type in 2023

Based on Age Group segmentation, Adults were the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Distribution Channel segmentation, Hospital pharmacies were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Influenza Medications Market- Segmentation Analysis:

The Global Influenza Medications Market is segmented based on Drug Type, Influenza Type, Age Group, Route of Administration, Distribution Channel, and Region.

The market is segmented into three classifications according to Drug Type: Antiviral drugs, Antihistamines, and Analgesics and Antipyretics. Antiviral drugs hold a dominant position in the market. These drugs are formulated to alleviate the intensity and length of flu symptoms, and in certain instances, they may also avert complications.

The market is classified into two segments according to the influenza type: Influenza A and Influenza B. Influenza A holds a predominant position in the market. It is recognized for its role in triggering yearly flu epidemics and possesses the capacity to result in pandemics owing to its rapid mutation capabilities.

The market is classified into three segments according to age groups: Adults, Pediatric, and Geriatric. The Adult segment dominates the market. The Influenza Medications Market focused on adults represents a crucial segment, given that adults frequently experience seasonal influenza, with the severity of the illness influenced by factors such as age, underlying health conditions, and vaccination history.

The market is segmented into three categories according to the route of administration: Oral, Inhaled, and Intravenous. The Oral category holds a dominant position in the market. Oral antiviral medications are frequently the primary option for combating influenza, especially in the treatment of mild to moderate cases.

The market is segmented into three distinct categories according to the Distribution Channel: Hospital pharmacies, Retail pharmacies, and online pharmacies. Hospital pharmacies dominate the market. Hospitals necessitate efficient antiviral treatments to care for patients who are at an increased risk of severe outcomes, including the elderly, individuals with pre-existing health conditions, and those with compromised immune systems.

Influenza Medications Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads the market, driven by an increase in the adoption of advanced drug therapies and a rise in healthcare spending. The regulatory framework in North America, especially in the United States, facilitates the expedited approval and implementation of new influenza treatments. This includes access to innovative therapies that may not yet be accessible in other regions. In 2022, a total of 37 new drugs, referred to as novel drugs, were approved for the first time in the U.S. Additionally, previously approved drugs were authorized for new applications, including new indications and patient demographics, as reported by the National Center for Health Statistics. Europe positions as the second largest region for market expansion, attributed to increasing awareness and early diagnosis.

Influenza Medications Market- Competitive Landscape:

The Influenza Medications Market exhibits a high level of competitiveness, characterized by numerous pharmaceutical firms striving to secure a larger share, especially within the antiviral sector. A significant focus of this competition lies in the innovation of new antiviral medications that employ unique mechanisms of action. Firms that allocate resources towards research and development to formulate advanced influenza therapies capable of overcoming resistance and providing enhanced efficacy or convenience are strategically positioning themselves to seize future market opportunities. Additionally, these companies are working to establish a robust presence in emerging markets, where a substantial population and a rising incidence of influenza present considerable sales potential. There is also a concerted effort among companies to promote awareness regarding the advantages of early antiviral intervention, particularly during the flu season.

Recent Developments:

In May 2024, AstraZeneca is set to present new clinical and real-world findings from its prominent inhaled, biologic, and early-stage respiratory portfolio at the American Thoracic Society (ATS) International Conference, taking place in San Diego, CA, from May 17 to May 22, 2024. The company will unveil 59 abstracts, which include 12 late-breaking posters, concentrating on the unmet needs associated with chronic obstructive pulmonary disease (COPD), severe asthma, and eosinophilic granulomatosis with polyangiitis (EGPA), along with other chronic respiratory conditions.

In October 2023, Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announced a partnership aimed at the co-development and co-commercialization of the asset TEV'574. This asset is presently undergoing Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, both of which are forms of inflammatory bowel disease.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INFLUENZA MEDICATIONS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca plc
  • Teva Pharmaceutical Industries Ltd
  • BioCryst Pharmaceuticals, Inc.
  • Sanofi
  • Daiichi Sankyo Company
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • NATCO Pharma Limited
  • GlaxoSmithKline plc
  • Lupin
  • Others

GLOBAL INFLUENZA MEDICATIONS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antiviral Drugs
  • Single Antiviral Drugs
  • Combination Antiviral Drugs
  • Antihistamines
  • Analgesics
  • Antipyretics

GLOBAL INFLUENZA MEDICATIONS MARKET, BY INFLUENZA TYPE- MARKET ANALYSIS, 2019 - 2032

  • Influenza A
  • Influenza B

GLOBAL INFLUENZA MEDICATIONS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Adults
  • Pediatric
  • Geriatric

GLOBAL INFLUENZA MEDICATIONS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Inhaled
  • Intravenous

GLOBAL INFLUENZA MEDICATIONS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL INFLUENZA MEDICATIONS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Influenza Medications Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Influenza Medications Market Snippet by Drug Type
    • 2.1.2. Influenza Medications Market Snippet by Influenza Type
    • 2.1.3. Influenza Medications Market Snippet by Age Group
    • 2.1.4. Influenza Medications Market Snippet by Route of Administration
    • 2.1.5. Influenza Medications Market Snippet by Distribution Channel
    • 2.1.6. Influenza Medications Market Snippet by Country
    • 2.1.7. Influenza Medications Market Snippet by Region
  • 2.2. Competitive Insights

3. Influenza Medications Key Market Trends

  • 3.1. Influenza Medications Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Influenza Medications Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Influenza Medications Market Opportunities
  • 3.4. Influenza Medications Market Future Trends

4. Influenza Medications Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Influenza Medications Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Influenza Medications Market Landscape

  • 6.1. Influenza Medications Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Influenza Medications Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Antiviral Drugs
      • 7.1.2.1. Single Antiviral Drugs
      • 7.1.2.2. Combination Antiviral Drugs
    • 7.1.3. Antihistamines
    • 7.1.4. Analgesics
    • 7.1.5. Antipyretics

8. Influenza Medications Market - By Influenza Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Influenza Type, 2023 & 2032 (%)
    • 8.1.2. Influenza A
    • 8.1.3. Influenza B

9. Influenza Medications Market - By Age Group

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Age Group, 2023 & 2032 (%)
    • 9.1.2. Adults
    • 9.1.3. Pediatric
    • 9.1.4. Geriatric

10. Influenza Medications Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 10.1.2. Oral
    • 10.1.3. Inhaled
    • 10.1.4. Intravenous

11. Influenza Medications Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital Pharmacies
    • 11.1.3. Retail Pharmacies
    • 11.1.4. Online Pharmacies

12. Influenza Medications Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Influenza Medications Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Influenza Medications Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Influenza Medications Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Influenza Medications Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Influenza Medications Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Influenza Medications Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. AstraZeneca plc
    • 13.2.2. Teva Pharmaceutical Industries Ltd
    • 13.2.3. BioCryst Pharmaceuticals, Inc.
    • 13.2.4. Sanofi
    • 13.2.5. Daiichi Sankyo Company
    • 13.2.6. Novartis AG
    • 13.2.7. F. Hoffmann-La Roche AG
    • 13.2.8. NATCO Pharma Limited
    • 13.2.9. GlaxoSmithKline plc
    • 13.2.10. Lupin
    • 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us